How to buy iBio shares | $2.43
Own iBio shares in just a few minutes.
iBio, Inc is a biotechnology business with stocks listed in the US. iBio shares (IBIO) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was US$2.43 – an increase of 20.9% over the previous week.
How to buy shares in iBio
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for iBio. Find the share by name or ticker symbol: IBIO. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until iBio reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$2.43, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of iBio, depending on your broker.
- Check in on your investment. Congratulations, you own a part of iBio. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
How has coronavirus impacted iBio's share price?
Since the stock market crash in March caused by coronavirus, iBio's share price has had significant positive movement.
Its last market close was US$2.43, which is 87.70% up on its pre-crash value of US$0.299 and 860.85% up on the lowest point reached during the March crash when the shares fell as low as US$0.2529.
If you had bought US$1,000 worth of iBio shares at the start of February 2020, those shares would have been worth US$4,558.82 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth US$8,933.82.
iBio share priceUse our graph to track the performance of IBIO stocks over time.
iBio shares at a glance
|Latest market close||USD$2.43|
|52-week range||USD$0.05 - USD$7.45|
|50-day moving average||USD$2.5374|
|200-day moving average||USD$2.0146|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.943|
Standard brokerage - US shares
Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.
- $0 brokerage for US stocks
- Trades starting from $50
- Fractional shares
- Copy top traders
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy iBio stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
iBio price performance over time
|1 week (2020-09-14)||14.62%|
|1 month (2020-08-21)||42.94%|
|3 months (2020-06-19)||65.31%|
|6 months (2020-03-20)||85.50%|
|1 year (2019-09-20)||305.00%|
|2 years (2018-09-21)||173.03%|
|3 years (2017-09-21)||599.88%|
|5 years (2015-09-21)||245.86%|
|Revenue TTM||US$1.3 million|
|Gross profit TTM||US$2 million|
|Return on assets TTM||-23.99%|
|Return on equity TTM||-320.62%|
|Market capitalisation||US$422.1 million|
TTM: trailing 12 months
Shorting iBio shares
There are currently 16.0 million iBio shares held short by investors – that's known as iBio's "short interest". This figure is 73.6% up from 9.2 million last month.
There are a few different ways that this level of interest in shorting iBio shares can be evaluated.
iBio's "short interest ratio" (SIR)
iBio's "short interest ratio" (SIR) is the quantity of iBio shares currently shorted divided by the average quantity of iBio shares traded daily (recently around 34.8 million). iBio's SIR currently stands at 0.46. In other words for every 100,000 iBio shares traded daily on the market, roughly 460 shares are currently held short.
However iBio's short interest can also be evaluated against the total number of iBio shares, or, against the total number of tradable iBio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case iBio's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 iBio shares in existence, roughly 90 shares are currently held short) or 0.112% of the tradable shares (for every 100,000 tradable iBio shares, roughly 112 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against iBio.
Find out more about how you can short iBio stock.
iBio share dividends
We're not expecting iBio to pay a dividend over the next 12 months.
Have iBio's shares ever split?
iBio's shares were split on a 1:10 basis on 10 June 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your iBio shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for iBio shares which in turn could have impacted iBio's share price.
iBio share price volatility
Over the last 12 months, iBio's shares have ranged in value from as little as US$0.05 up to US$7.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while iBio's is -5.9482. This would suggest that iBio's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, iBio has bucked the trend.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of pre-clinical development, regulatory approval, commercial product launch, and on-going commercial phase requirements. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. The company is also developing vaccine candidates for third parties. It has a license agreement with the University of Natural Resources and Life Sciences, Vienna; a strategic relationship with Beijing CC-Pharming Ltd.; and collaboration agreements with AzarGen Biotechnologies (Pty) Ltd, The Texas A&M University System, and Fraunhofer Center for Molecular Biotechnology. In addition, the company offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
Frequently asked questions
Ask an Expert